Damora Therapeutics, INC. (DMRA) — SEC Filings

Overview

Damora Therapeutics, INC. (DMRA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Mar 25, 2026: This Form 4 filing indicates that Turtle Cameron, a reporting person, filed a statement of changes in beneficial ownership of securities for Damora Therapeutics, Inc. on March 25, 2026, for a period ending March 23, 2026. While the filing itself doesn't detail specific transactions, it signals that

Sentiment Summary

Across 28 filings, the sentiment breakdown is: 2 bearish, 25 neutral, 1 mixed. The dominant filing sentiment for Damora Therapeutics, INC. is neutral.

Filing Type Overview

Damora Therapeutics, INC. (DMRA) has filed 2 3, 3 4, 2 DEF 14A, 1 8-K/A, 9 8-K, 6 10-Q, 2 10-K, 2 SC 13G/A, 1 SC 13D/A with the SEC between Mar 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (28)

• 4 Filing — 4 · Apr 1, 2026
• Damora Therapeutics: Insider Ownership Change Filed by Turtle Cameron — 4 · Mar 25, 2026
  This Form 4 filing indicates that Turtle Cameron, a reporting person, filed a statement of changes in beneficial ownership of securities for Damora Therapeutics
• Damora Therapeutics: Insider Ownership Change Filed — 4 · Mar 25, 2026
  This Form 4 filing, submitted on March 25, 2026, indicates a change in beneficial ownership for Damora Therapeutics, Inc. (Issuer CIK: 0001800315) by Michael La
• Turtle Cameron Files Form 3 for Damora Therapeutics, Inc. — 3 · Mar 25, 2026
  Turtle Cameron, a reporting person, filed an initial statement of beneficial ownership (Form 3) for Damora Therapeutics, Inc. on March 25, 2026, indicating thei
• Damora Therapeutics: Michael Landsittel Joins as Insider, Files Form 3 — 3 · Mar 25, 2026
  This Form 3 filing, dated March 25, 2026, indicates that Michael Landsittel has become an insider at Damora Therapeutics, Inc. (CIK: 0001800315). As an initial
• Galecto Seeks Shareholder Nod for Cayman Move, Stock Issuance — DEF 14A · Dec 31, 2025 Risk: medium
  Galecto, Inc. (DMRA) is seeking stockholder approval for six key proposals at a Special Meeting on February 9, 2026, including the issuance of common stock upon
• Galecto, Inc. Files Amendment to 8-K Report — 8-K/A · Dec 9, 2025 Risk: low
  Galecto, Inc. filed an amendment (8-K/A) on December 9, 2025, to its current report originally filed on November 10, 2025. This amendment pertains to Item 5.03,
• Galecto, Inc. Files 8-K with Key Corporate Updates — 8-K · Nov 10, 2025 Risk: medium
  On November 10, 2025, Galecto, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agreement, the c
• Galecto's Cash Dwindles Amid Strategic Shift, Going Concern Doubts Mount — 10-Q · Nov 6, 2025 Risk: high
  Galecto, Inc. (GLTO) reported a net loss of $3.133 million for the three months ended September 30, 2025, an improvement from a net loss of $3.883 million in th
• Galecto's Cash Dwindles Amidst Continued Losses — 10-Q · Aug 5, 2025 Risk: high
  Galecto, Inc. (DMRA) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercialization stage. The company's net lo
• Galecto, Inc. Files 8-K on Security Holder Vote Matters — 8-K · Jun 20, 2025 Risk: low
  Galecto, Inc. filed an 8-K on June 20, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 18, 2025. The company, inc
• Galecto, Inc. Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
  Galecto, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including stock option and grant plans from 2020 an
• Galecto Inc. Files 2025 Proxy Statement — DEF 14A · Apr 30, 2025 Risk: low
  Galecto, Inc. filed its definitive proxy statement (DEF 14A) on April 30, 2025, for the fiscal year ending December 31, 2024. The filing concerns the company's
• 10-K Filing — 10-K · Mar 19, 2025
• SC 13G/A Filing — SC 13G/A · Nov 7, 2024
• Galecto, Inc. Files Q3 2024 10-Q — 10-Q · Nov 1, 2024 Risk: medium
  Galecto, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position and business operations. Key events includ
• Galecto, Inc. Files 8-K: Board and Compensation Changes — 8-K · Oct 15, 2024 Risk: medium
  On October 15, 2024, Galecto, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates
• 8-K Filing — 8-K · Oct 7, 2024
• Galecto, Inc. Files 8-K Report — 8-K · Sep 18, 2024 Risk: medium
  On September 16, 2024, Galecto, Inc. filed an 8-K report to disclose other events. The filing does not contain specific details regarding the nature of these ev
• Galecto Regains Rights to Galectin-3 Program from BMS — 8-K · Sep 11, 2024 Risk: medium
  On September 10, 2024, Galecto, Inc. announced the termination of its collaboration and license agreement with Bristol Myers Squibb Company. This termination is
• Galecto, Inc. Files 8-K for Bylaw Amendments & Financials — 8-K · Sep 5, 2024 Risk: low
  Galecto, Inc. filed an 8-K on August 29, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, incorporat
• SC 13G/A Filing — SC 13G/A · Aug 29, 2024
• Galecto, Inc. Files Q2 2024 10-Q — 10-Q · Aug 12, 2024 Risk: medium
  Galecto, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates. Key financial data points an
• Novo Holdings Ups Galecto Stake to 10% — SC 13D/A · Jun 24, 2024 Risk: medium
  Novo Holdings A/S has amended its Schedule 13D filing for Galecto, Inc. on June 24, 2024. The filing indicates a change in beneficial ownership, with Novo Holdi
• Galecto, Inc. Holds Annual Stockholder Meeting — 8-K · Jun 21, 2024 Risk: low
  On June 20, 2024, Galecto, Inc. filed an 8-K report indicating that it held its Annual Meeting of Stockholders. During this meeting, the company's stockholders
• Galecto, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · Apr 29, 2024 Risk: medium
  Galecto, Inc. (DMRA) filed a Quarterly Report (10-Q) with the SEC on April 29, 2024. Galecto, Inc. filed a 10-Q report for the period ending March 31, 2024. The
• Galecto, Inc. Files 8-K Report — 8-K · Mar 26, 2024 Risk: low
  On March 22, 2024, Galecto, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific transactions or financial figure
• Galecto, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 8, 2024 Risk: medium
  Galecto, Inc. (DMRA) filed a Annual Report (10-K) with the SEC on March 8, 2024. Galecto, Inc. filed its 2023 Form 10-K on March 8, 2024. The filing covers the

Risk Profile

Risk Assessment: Of DMRA's 19 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Damora Therapeutics, INC.'s most recent 10-Q filing (Nov 6, 2025):

• Revenue: N/A
• Net Income: -$9.103M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $7.606M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Carl Goldfischer
• Lori Firmani
• Garrett Winslow
• Hans T. Schambye, MD PhD

Industry Context

Galecto operates in the highly competitive biotechnology sector, focusing on developing novel therapies for fibrotic diseases and cancer. The industry is characterized by long development cycles, significant R&D investment, and reliance on clinical trial success and regulatory approvals. Companies often pursue strategic partnerships or financing rounds to fund their pipeline development.

Top Tags

corporate-governance (7) · 10-Q (4) · ownership-change (3) · SEC Filing (3) · insider-filing (2) · form-4 (2) · form-3 (2) · Biotechnology (2) · Clinical Stage (2) · Going Concern (2)

Key Numbers

• Current authorized shares of Common Stock: 300,000,000 — Proposed to increase to 500,000,000 shares
• Proposed authorized shares of Common Stock: 500,000,000 — An increase of 200,000,000 shares from the current authorization
• Shares of Common Stock outstanding: 1,597,321 — As of the record date, December 29, 2025, entitled to vote
• Shares of Common Stock from Asset Acquisition: 265,309 — Not entitled to vote on Proposal No. 1 for Nasdaq listing rules
• Shares of Series B Preferred Stock: 16,366 — Issued and outstanding, subject to conversion approval
• Shares of Series C Preferred Stock: 43,882 — Issued and outstanding, subject to conversion approval
• Special Meeting start time: 9:00 a.m. Eastern Time — On February 9, 2026, via live webcast
• Quorum requirement: 33 1/3% — Percentage of outstanding shares required for transaction of business
• Par value per share: $0.00001 — For Common Stock, Series B Preferred Stock, and Series C Preferred Stock
• Galecto's Copenhagen phone number: 70 70 52 10 — Contact information for the company's principal executive offices
• SEC File Number: 001-39655 — Identifies the specific SEC filing for Galecto, Inc.
• IRS Employer Identification No.: 37-1957007 — Tax identification number for Galecto, Inc.
• Cash and cash equivalents: $7.606M — as of September 30, 2025, down from $14.175M at Dec 31, 2024, insufficient for 12 months
• Net loss for nine months: $9.103M — ended September 30, 2025, an improvement from $14.698M in 2024
• Net loss for three months: $3.133M — ended September 30, 2025, an improvement from $3.883M in 2024

Related Companies

GLTO · BMY

Frequently Asked Questions